FUJIFILM Diosynth Biotechnologies is the contract development and manufacturing organization (CDMO) arm of FUJIFILM Corporation, a global technology company headquartered in Tokyo, Japan, with over 70,000 employees worldwide. The business specializes in helping partners develop and manufacture vaccines, gene therapies, and other biologics, with technical capabilities spanning lipid nanoparticles (LNPs), liposomes, mRNA synthesis, and advanced GMP manufacturing technologies.
Manufacturing operations are anchored by GMP-compliant facilities in Denmark and the United States, with additional sites across other global locations. These facilities operate within a broader FUJIFILM group that spans healthcare, diagnostics, medical systems, regenerative medicine, electronics, and imaging - a portfolio that has its roots in photographic film and has since expanded substantially into life sciences and biopharmaceutical manufacturing.
On the scientific and technical side, the organization's CDMO work covers the full development-to-manufacture pathway for complex biological products. Core areas of expertise include:
- Vaccine development and manufacturing
- Gene therapy development and manufacturing
- Lipid nanoparticle and liposome formulation
- mRNA synthesis
- GMP biologics manufacturing
The company states that its sites are powered by 100% renewable energy, reflecting a stated commitment to sustainability. FUJIFILM Diosynth Biotechnologies operates under FUJIFILM's broader mission of "Value from Innovation," positioning its CDMO services as a collaborative model in which it acts as a manufacturing and development partner to biopharmaceutical organizations globally.
